MASTL — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL27333023	1.00	6/20
SCHEMBL27333042	1.00	6/20
SCHEMBL27333165	1.00	6/20
SCHEMBL27335040	1.00	6/20
SCHEMBL27335119	1.00	6/20
SCHEMBL27335262	1.00	6/20
SCHEMBL27335264	1.00	6/20
SCHEMBL27335951	1.00	6/20
SCHEMBL27333003	0.85	6/20
SCHEMBL30770775	0.85	6/20
SCHEMBL27333220	0.84	6/20
SCHEMBL27335357	0.84	6/20
SCHEMBL27333298	0.83	6/20
SCHEMBL27333300	0.83	6/20
SCHEMBL27333206	0.77	6/20
SCHEMBL27333311	0.76	6/20
SCHEMBL27333230	0.75	6/20
SCHEMBL27333295	0.75	6/20
SCHEMBL27333301	0.75	6/20
SCHEMBL30770743	0.75	6/20

Clinical trials — most relevant to MASTL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis	PHASE3	COMPLETED
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment	PHASE3	UNKNOWN
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients	PHASE3	NOT_YET_RECRUITING
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients	PHASE3	RECRUITING
Masitinib in Patients With Mild to Moderate Alzheimer's Disease	PHASE3	COMPLETED
Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels	PHASE3	COMPLETED
Masitinib in Patients With Mild Alzheimer's Disease	PHASE3	NOT_YET_RECRUITING
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis	PHASE3	COMPLETED
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer	PHASE3	COMPLETED
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis	PHASE3	COMPLETED
Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids	PHASE3	COMPLETED
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia	PHASE2	COMPLETED
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome	PHASE2	UNKNOWN
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer	PHASE2	COMPLETED
Midostaurin in Indolent Systemic Mastocytosis	PHASE2	UNKNOWN
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Allergy and Immunology Natural History Study	nan	RECRUITING
Cause and Natural Course of Pediatric-Onset Mastocytosis	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MASTL binder may also engage these)

Protein	Name	Similarity
D2HXI8	—	1.000	D2HXI8 →
Q8C0P0	—	1.000	Q8C0P0 →
Q6NTJ3	—	0.999	Q6NTJ3 →
E1BFR5	—	0.997	E1BFR5 →
P46200	—	0.996	P46200 →
E2RJI4	—	0.995	E2RJI4 →
Q6DBX4	—	0.995	Q6DBX4 →
P10244	—	0.995	P10244 →
B1WAR9	—	0.993	B1WAR9 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.993	landscape →
E1C2I2	—	0.993	E1C2I2 →
P52550	—	0.992	P52550 →
Q05935	—	0.992	Q05935 →
A7MBB4	—	0.992	A7MBB4 →
Q03237	—	0.991	Q03237 →
Q90ZS6	—	0.991	Q90ZS6 →
Q5DW34	—	0.990	Q5DW34 →
Q949U2	—	0.990	Q949U2 →
P01103	—	0.990	P01103 →
Q9SJM3	—	0.990	Q9SJM3 →
Q9SB51	—	0.990	Q9SB51 →
Q9NYI0	—	0.990	Q9NYI0 →
Q6KAQ7	—	0.989	Q6KAQ7 →
A6QP06	—	0.989	A6QP06 →
Q3YC04	—	0.989	Q3YC04 →
Q8VII8	—	0.989	Q8VII8 →
KMT5B	Histone-lysine N-methyltransferase KMT5B	0.989	landscape →
Q811D2	—	0.989	Q811D2 →
Q5R8X7	—	0.989	Q5R8X7 →
Q94CU5	—	0.989	Q94CU5 →